drugset

drugset / Trial / NCT00979927

SPC3649 Multiple Dose Study in Healthy Volunteers

NCT00979927 ↗

Phase 1 Completed 30 enrolled Santaris Pharma A/S

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the safety and tolerability of SPC3649 given in multiple doses to healthy volunteers.

Timeline

Start: 2009-09
Primary completion: 2010-09
Completion: 2010-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Miravirsen	Antisense oligonucleotide	—	—

Indications